Rational antibiotic treatment of outpatient genitourinary infections in a changing environment

American Journal of Medicine

Volumn 118, Issue 7 SUPPL., 2005, Pages 7-13

  David, Richard D ^a   DeBlieux, Peter M C ^b,d   Press, Robert ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Antibiotics; Fluoroquinolones; Genitourinary infections; Prostatitis; Pyelonephritis; Urinary tract infections

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFALOTIN; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; GATIFLOXACIN; LEVOFLOXACIN; NITROFURANTOIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; BACTERICIDAL ACTIVITY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIARRHEA; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG COST; DRUG PENETRATION; DRUG PREFERENCE; DRUG SAFETY; ENVIRONMENTAL FACTOR; ESCHERICHIA COLI; EVIDENCE BASED MEDICINE; HUMAN; INTESTINE FLORA; MEDICAL SOCIETY; MORBIDITY; OUTPATIENT; PRIORITY JOURNAL; PROSTATITIS; PYELONEPHRITIS; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT PLANNING; UROGENITAL TRACT INFECTION;

EID: 21744440395     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.05.008     Document Type: Article

References (42)

1. K. Gupta, T.M. Hooton, W.E. Stamm Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections Ann Intern Med. 135 2001 41 50
2. B. Foxman Epidemiology of urinary tract infections incidence, morbidity, and economic costs Am J Med. 113 suppl 2002 5S 13S
3. B. Foxman Epidemiology of urinary tract infections incidence, morbidity, and economic costs Dis Mon. 49 2003 53 70
4. J.W. Warren, E. Abrutyn, J.R. Hebel, J.R. Johnson, A.J. Schaeffer, W.E. Stamm Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women Clin Infect Dis. 29 1999 745 758
5. T.M. Hooton Pathogenesis of urinary tract infections an update J Antimicrob Chemother. 46 2000 1 7
6. A.E. Stapleton Urinary tract infections in healthy women Curr Treat Opt Infect Dis. 5 2003 43 51
7. A.J. Schaeffer Diagnosis and management of prostatitis Brazilian Journal of Urology 26 2000 122 131
8. L.E. Nicolle Epidemiology of urinary tract infection Infect Med. 18 2001 153 162
9. T.M. Hooton, W.E. Stamm Diagnosis and treatment of uncomplicated urinary tract infection Infect Dis Clin North Am. 11 1997 551 581
10. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases) National guideline for the management of prostatitis Sex Transm Infect. 75 suppl 1 1999 S46 S50
11. G.S. Jack, S.I. Zeitlin Confronting prostatitis is your management strategy up-to-date? Contemp Urol. 16 2004 34 46
12. J. McCue UTIs in at-risk patients are they complicated? Infect Med. 16 1999 533 540
13. W. Bundrick, S.P. Heron, P. Ray Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis a randomized double-blind multicenter study Urology 62 2003 537 541
14. Trovan® (trovafloxacin) New Drug Application. US Food and Drug Administration Web site. Available at: http://www.fda.gov/cder/foi/nda/97/ 020760a_medr_P6.pdf. Accessed October 13, 2004.
15. G. Dow, P. Rao, G. Harding A prospective, randomized trial of 3 of 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury Clin Infect Dis. 39 2004 658 664
16. L. Nicolle Best pharmacological practice urinary tract infections Expert Opin Pharmacother. 4 2003 693 704
17. K.G. Naber Short-term therapy of acute uncomplicated cystitis Curr Opin Urol. 9 1999 57 64
18. D.N. Gilbert, R.C. Moellering Jr, G.M. Eliopoulos, M.A. Sande The Sanford Guide to Antimicrobial Therapy 34th ed. 2004 Antimicrobial Therapy, Inc Hyde Park, VT
19. Data on file. The Surveillance Network (TSN) Database 2003 2003 Ortho-McNeil Pharmaceutical, Inc Raritan, NJ
20. W.E. Stamm, S.R. Norrby Urinary tract infections disease panorama and challenges J Infect Dis 183 suppl 1 2001 S1 S4
21. L.E. Nicolle Urinary tract infection traditional pharmacologic therapies Am J Med 113 suppl 1A 2002 35S 44S
22. K. Gupta, D.F. Sahm, D. Mayfield, W.E. Stamm Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women a nationwide analysis Clin Infect Dis. 33 2001 89 94
23. W.E. Lummus, I. Thompson Prostatitis Emerg Med Clin North Am. 19 2001 691 707
24. J.E. Fowler Jr Antimicrobial therapy for bacterial and nonbacterial prostatitis Urology 60 2002 24 26
25. G.G. Zhanel, K. Ennis, L. Vercaigne A critical review of the fluoroquinolones focus on respiratory infections Drugs 62 2002 13 59
26. G.L. Drusano, S.L. Preston, M. Van Guilder A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin Antimicrob Agents Chemother. 44 2000 2046 2051
27. D. Nicolau Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections J Antimicrob Chemother 50 suppl S1 2002 61 70
28. T.B. Giblin, R.L. Sinkowitz-Cochran, P.L. Harris CDC Campaign to Prevent Antimicrobial Resistance Team Clinicians' perceptions of the problem of antimicrobial resistance in health care facilities Arch Intern Med. 164 2004 1662 1668
29. D.A. Talan, W.E. Stamm, T.M. Hooton Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women a randomized trial JAMA 283 2000 1583 1590
30. Data on file. Proceedings of the TRUST 8 (2004) Investigators' Meeting; May 25, 2004; New Orleans, LA. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc., 2004.
31. Data on file. Proceedings of the TRUST 7 (2002-2003) Surveillance Study. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc., 2003.
32. D.F. Sahm, C. Thornsberry, D.C. Mayfield, M.E. Jones, J.A. Karlowsky Multidrug-resistant urinary tract isolates of Escherichia coli prevalence and patient demographics in the United States in 2000 Antimicrob Agents Chemother. 45 2001 1402 1406
33. M.J. Hepburn, D.P. Dooley, P.J. Skidmore, M.W. Ellis, W.F. Starnes, W.C. Hasewinkle Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis Arch Intern Med. 164 2004 1669 1674
34. G.G. Zhanel, M. Walters, N. Laing, D.J. Hoban In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae J Antimicrob Chemother. 47 2001 435 440
35. M.E. Klepser, E.J. Ernst, C.R. Petzold, P. Rhomberg, G.V. Doern Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model Antimicrob Agents Chemother. 45 2001 673 678
36. H. Liu, S.G. Mulholland Appropriate antibiotic treatment of genitourinary infections in hospitalized patients Am J Med. 118 suppl 7A 2005 14S 20S
37. P. Kardas Patient compliance with antibiotic treatment for respiratory tract infections J Antimicrob Chemother. 49 2002 897 903
38. T.M. File Jr Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia Clin Infect Dis. 39 suppl 3 2004 S159 S164
39. A.J. Claxton, J. Cramer, C. Pierce A systematic review of the associations between dose regimens and medication compliance Clin Ther. 23 2001 1296 1310
40. Levaquin [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc.; 2004.
41. Cipro [package insert]. West Haven, CT: Bayer Pharmaceuticals Corporation; 2004.
42. Tequin [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2004.